Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Patisiran: APOLLO-B OLE Study

Standard response letter on the APOLLO-B OLE study of patisiran.

Musculoskeletal manifestations in patients with ATTR amyloidosis: Evidence from real-world analyses and clinical trials

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Vutrisiran: Post-Hoc Analysis of HELIOS-A Results by Baseline NIS Quartile

Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.

APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-label Extension Period

Gene Silencing Therapeutics in Cardiology: A Review Article

Vutrisiran: Randomized Treatment Extension Period of the HELIOS-A Study

Standard response letter on vutrisiran and results from a 9-month analysis of the randomized treatment extension period of HELIOS-A.

Vutrisiran: Pain in Extremity

Standard response letter on vutrisiran and the adverse event of pain in extremity.

Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.